Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Treasury Shares: 2014-2024

Historic Treasury Shares for Cartesian Therapeutics (RNAC) over the last 8 years, with Dec 2024 value amounting to $444,238.

  • Cartesian Therapeutics' Treasury Shares rose 16.74% to $523,254 in Q3 2025 from the same period last year, while for Sep 2025 it was $523,254, marking a year-over-year increase of 16.74%. This contributed to the annual value of $444,238 for FY2024, which is N/A change from last year.
  • Per Cartesian Therapeutics' latest filing, its Treasury Shares stood at $444,238 for FY2024, which was down 73.95% from $1.7 million recorded in FY2022.
  • Cartesian Therapeutics' 5-year Treasury Shares high stood at $1.7 million for FY2022, and its period low was $87,500 during FY2020.
  • Moreover, its 2-year median value for Treasury Shares was $1.1 million (2022), whereas its average is $1.1 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Treasury Shares tumbled by 51.72% in 2020 and then skyrocketed by 350.80% in 2021.
  • Yearly analysis of 4 years shows Cartesian Therapeutics' Treasury Shares stood at $87,500 in 2020, then soared by 350.80% to $394,450 in 2021, then skyrocketed by 332.39% to $1.7 million in 2022, then reached $444,238 in 2024.